Neuralink’s CAN-PRIME study in Toronto is an early-feasibility trial of its N1 implant and R1 surgical robot. Its practical value is that it puts the whole system—implant, robot, hospital team, and patient follow-up—into a real clinical setting. It does not establish that the device is approved or proven to restore function.
Neuralink’s Canadian clinical study is worth understanding because it tests more than a brain implant.
CAN-PRIME is evaluating Neuralink’s N1 implant alongside the company’s R1 surgical robot. ClinicalTrials.gov describes the study as an early-feasibility investigation intended to evaluate a precise robotically implanted brain-computer interface for control of external devices.
That phrase matters.
An early-feasibility study is designed to investigate whether a system can be used and evaluated in a limited clinical setting. It is not the same as a completed large-scale trial. It is not proof that a device works for everyone. And it is not a product people can simply buy.
University Health Network says Toronto Western Hospital performed the first Neuralink implant surgeries outside the United States in 2025. MobiHealthNews reported that Vancouver police sergeant Lee Marten later received the implant through the Canadian study after ALS severely limited his movement.
The N1 implant is intended to capture selected brain signals and translate them into commands for an external device. The R1 robot is part of the same system: it places extremely fine electrode threads during surgery.
That pairing is the actual story. An implanted BCI is not just hardware. It depends on surgical workflow, clinical monitoring, participant support, software performance, and follow-up over time.
A person controlling a screen shortly after an implant can be encouraging. The larger questions take longer: Are procedures repeatable? Are there complications? Do signals remain stable? Can participants use the system reliably at home? Does the system create meaningful independence in ordinary life?
Readers should also separate authorization to study a device from approval to sell a treatment. A regulator allowing a clinical investigation means researchers can gather evidence under defined conditions. It does not mean the regulator has decided that the device is safe and effective for broad public use.
The practical takeaway is simple: when a Neuralink headline appears, ask which stage it describes. Is it a company demonstration, a personal participant story, a clinical study, permission to conduct research, a completed trial, or an approved treatment?
CAN-PRIME belongs in the clinical-research category. It is a serious step because it brings the implant-and-robot system into a Canadian hospital setting. But the evidence that matters next is not more branding. It is careful follow-up on safety, repeatability, durability, and the everyday usefulness participants experience.
The most useful future updates will report procedure- and device-related adverse events, plus whether participants can use the system consistently over time.
Bottom Line
CAN-PRIME is a serious early-feasibility study of an implant-and-robot clinical system, not an approved or commercially available treatment.